Letolizumab

From WikiMD's Medical Encyclopedia

Revision as of 12:56, 18 March 2025 by Prab (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Letolizumab is a monoclonal antibody designed for the treatment of autoimmune diseases. It is currently under development by Biocon Biologics and Viatris.

History[edit]

Letolizumab was originally developed by Biocon Biologics, a subsidiary of Biocon, an Indian biopharmaceutical company. In 2020, Biocon Biologics partnered with Viatris, a global healthcare company, to further develop and commercialize the drug.

Mechanism of Action[edit]

Letolizumab is a monoclonal antibody that targets the CD6 protein, a surface molecule present on T cells. By binding to CD6, letolizumab inhibits the activation and proliferation of T cells, thereby reducing the immune response that contributes to autoimmune diseases.

Clinical Trials[edit]

Letolizumab has undergone several clinical trials to evaluate its safety and efficacy in treating autoimmune diseases. These trials have shown promising results, with letolizumab demonstrating a good safety profile and potential efficacy in reducing symptoms of autoimmune diseases.

Potential Uses[edit]

Letolizumab is being investigated for use in a variety of autoimmune diseases, including rheumatoid arthritis, psoriasis, and multiple sclerosis. Further clinical trials are needed to confirm its efficacy and safety in these conditions.

See Also[edit]

This article is a medical stub. You can help WikiMD by expanding it!
PubMed
Wikipedia


Stub icon
   This article is a medical stub. You can help WikiMD by expanding it!
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

W8MD's happy loser(weight)

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

  • Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
  • Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends

Learn more:

Advertise on WikiMD

WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Letolizumab&oldid=6524856"